ReviewMolecular diversity2026
Multicomponent reactions for protein tyrosine phosphatase inhibitors.
Review in Molecular diversity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Protein tyrosine phosphatases (PTPs) are pivotal regulators of cellular signaling and potential therapeutic targets for cancer, metabolic disorders, and autoimmune diseases. However, the development of PTP inhibitors remains challenging due to the highly conserved catalytic pocket, the poor membrane permeability of phosphotyrosine mimetics, and difficulties in achieving subtype selectivity. Multicomponent reactions (MCRs) offer a powerful solution by enabling the rapid and modular synthesis of structurally diverse, medicinally relevant scaffolds in a one-pot manner. Through the flexible combination of building blocks, MCRs facilitate efficient optimization of polarity, topology, conformational rigidity, and secondary-pocket engagement, thereby accelerating the discovery of selective and drug-like PTP inhibitors. This review provides the first systematic overview of MCR-enabled PTP inhibitor discovery. The discussion is organized according to major MCR strategies and PTP target classes, highlighting how MCR chemistry has been applied to rapidly construct focused libraries, identify novel scaffolds, and optimize potency and selectivity. Key design concepts-including phosphotyrosine mimicry, fragment extension, conformational constraint, and stereochemical control-are critically summarized. Current limitations and emerging opportunities, such as AI-assisted design, virtual screening, and dynamic combinatorial chemistry, are also discussed. By positioning MCRs as design-enabling technologies, this review outlines a practical framework for the development of next-generation PTP inhibitors.
Indexed as
Identifiers
42423920What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.